Conditions: Metastatic Breast Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 11
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the progression free survival (PFS) of metastatic ER, PR and HER2/neu negative breast cancers to the combination of carboplatin and bevacizumab (Avastin®) therapy.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: carboplatin intervention 2: bevacizumab
Intervention descriptions: intervention 1: AUC 6 in 250mL saline IV over 30 minutes intervention 2: 15mg/kg in 100mL saline IV over 60 - 90 minutes

Protocol document: